Targeting Clear Horizons
Finding the Path in Chronic Rhinosinusitis with Nasal Polyps
Clinical Practice Guidelines and Position Papers
EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management.
Bachert C, et al. J Allergy Clin Immunol. 2021;147(1):29-36.
Chronic rhinosinusitis with nasal polyps (CRSwNP) position paper, 2021.
Australasian Society of Clinical Immunology and Allergy (ASCIA).
European position paper on rhinosinusitis and nasal polyps, 2020.
Fokkens WJ, et al. Rhinology. 2020;58(suppl S29):1-464.
Clinical Practice Tools
Sino-Nasal Outcome Test (SNOT-22) Questionnaire
Sinus Control Test (SCT)
Questionnaire of Olfactory Disorders (QOD)
Patient Advocacy Organizations and Resources
Asthma and Allergy Foundation of America (AAFA)
AAFA is dedicated to improving the quality of life for people with asthma and allergic diseases including nasal polyps through education, advocacy, and research.
American Academy of Allergy, Asthma & Immunology (AAAAI)
AAAAI is dedicated to the advancement of the knowledge and practice of allergy, asthma, and immunology for optimal patient care.
Suggested Readings
Burden of disease in chronic rhinosinusitis with nasal polyps.
Bachert C, et al. J Asthma Allergy. 2021;14:127-134.
Phenotypes in chronic rhinosinusitis.
McCormick JP, et al. Curr Allergy Asthma Rep. 2020;20(7):20.
Biomarkers in chronic rhinosinusitis with nasal polyps.
Workman AD, et al. Immunol Allergy Clin North Am. 2018; 38(4):679-692.
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Bachert C, et al. Lancet. 2019;394(10209):1638-1650.
Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.
Gevaert P, et al. J Allergy Clin Immunol. 2020;146(3):595-605.
EValuating trEatment RESponses of dupilumab versus omalizumab in Type 2 patients: the EVEREST Trial.
Gomez LDP, et al. J Allergy Clin Immunol. 2022;149(2): Abstract 145.
Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomized, double-blind, placebo-controlled, phase 3 trial.
Han JK, et al. Lancet Respir Med. 2021;9(10):1141-1153.
Mepolizumab induced loss of smell improvement in patients with chronic rhinosinusitis with nasal polyps from the SYNAPSE Study.
Mullo J, et al. J Allergy Clin Immunol. 2022;149(2): Abstract 481.
Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial.
Bachert C, et al. J Allergy Clin Immunol. 2021;149(4):1309-1317.e12.
Finding the Path in Chronic Rhinosinusitis with Nasal Polyps
Relevant Resources
Improved Diagnostic and Management Strategies
Long-Term Management Strategies to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Differential Diagnosis and Comprehensive Management Strategies
Optimizing Maintenance Therapy Across Healthcare Settings
Evolving Strategies for Diagnosis and Long-Term Management
Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms
Improving Outcomes for Patients with COPD
Collaborative Approaches to Guideline-Concordant Patient Care
New Strategies for Individualizing Long-term Care
A New Era in Precision Medicine
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Pathophysiology to the Management of Moderate-to-Severe Disease
Evolving Best Practices to Optimize Outcomes
Consensus and Controversies on the Road to Precision Medicine
Targeting Immune Dysregulation and Delivering Comprehensive Care
Ongoing Monitoring, Pulmonary Rehabilitation, and Individualized Care
Translating Comprehensive Patient Evaluations Into Personalized Therapy
Looking Beyond Barriers to Optimize Therapy
New Perspectives on Targeting Remission and Individualizing Therapy
Debates and Discussions About Personalizing Patient Management
Using Imaging to Improve Patient Outcomes
Discussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs
Differential Diagnosis, Multidisciplinary Management, and Patient Engagement
From Guideline Recommendations to Daily Clinical Decision-Making
Translating Pathophysiology into Targeted Treatments
Think You Know JAK?
An Interactive Experience Highlighting Recent Clinical Advances
Improving Patient Outcomes Through Shared Clinical Decision Making
Debates & Discussions on the Evolving Role of JAK Inhibitors
Improving Patient Outcomes Through Shared Clinical Decision Making
Digging Deep on Shared Decision-Making
Clinical Resource Center
The Evolving Role of JAK Inhibitors
Unpacking the Evidence for Their Use Today and Tomorrow
A Case-Based Conversation on Managing Asthma and Chronic Rhinosinusitis With Nasal Polyposis
The Clinical and Utilization Benefits of Exacerbation Prevention
Mechanistic Insights and Emerging Treatment Options
A Focus on Exacerbation Prevention
Best Practices for Primary Care
Unlocking Novel Paths to Patient Care
Evolving Best Practices for Patient Management
The Increasing Role of JAK Inhibitors
Unlocking Novel Paths to Patient Care
Shared Decision-making in the Era of Biologics
New Pathways to Patient Management
A Focus on Clinical Evidence and Guideline Recommendations
From Comprehensive Patient Evaluations to Individualized Evidence-based Care
Preventing COPD Exacerbations to Improve Outcomes
A Whole Patient Case Series
Debates and Discussions about Monoclonal Antibody Therapies
An Update on Monoclonal Antibody Therapies
New Avenues to the Management of Severe Asthma
Getting on the Fast Track to Identify AxSpA
Evolving Best Practices for Pediatric Patients
Interdisciplinary Strategies for Adult and Pediatric Patients
Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema
Reducing LDL-C and a Lifetime of Cardiovascular Risk
A Multidisciplinary Look at Early Diagnosis and Management
Recent Developments in Anti-SARS-CoV-2 Monoclonal Antibodies for Treatment
Best Practices for Diagnosis and Management
New Avenues to Pre-Exposure Prophylaxis
New Pathways to Optimize Patient Outcomes
From Patient Evaluations to New Targeted Therapies
Debates and Discussions About New Upstream Treatment Avenues
A Case-Based Update on Pediatric Patients
